Business
Appointments of CSO and Head of R&D
ImmuPharma PLC announced the promotions of Dr. Sébastien Goudreau to Chief Scientific Officer and Dr. Laura Mauran-Ambrosino to Head of Research and Development. These appointments coincide with the filing of a new patent application for their lead asset, P140. The company believes this new patent on P140 is a major step forward. The company is moving forward with partnering and commercializing its product portfolio, particularly P140. Disclaimer*
About this update from Immupharma Plc
ImmuPharma PLC ("ImmuPharma" or the "Company") Appointments of Chief Scientific Officer and Head of R&D ImmuPharma PLC (LSE: IMM), a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics , announces key appointments, in conjunction with the filing of a groundbreaking new patent application for its lead asset P140, separately announced today. Recognising the significance of this major step forward, Dr Sébastien Goudreau has been promoted into the position of Chief Scientific Officer and Dr Laura Mauran-Ambrosino has been promoted to Head of Research and Development, of the Company. Commenting on this announcement, Tim McCarthy, CEO of ImmuPharma, said: "The new patent on P140 is a major step forward for the Company and is the result of the impressive and dedicated research conducted by both by Sébastien and Laura over the last two years. As we continue to move forward on the next step of our corporate journey, which is the partnering and commercialisation of our product portfolio, P140 in particular, it is important that our R&D team is at the forefront of our interactions and negotiations with current and future commercial partners. I and the Board congratulate both Sébastien and Laura on their new appointments and thank them for their innovation and hard work." Ends This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation no 596/2014 which is part of English law by virtue of the European (withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain. For further information please contact: ImmuPharma PLC ( www.immupharma.co.uk ) Tim McCarthy, Chief Executive Officer Lisa Baderoon, Head of Investor Relations +44 (0) 207 206 2650 + 44 (0) 7721 413496 SPARK Advisory Partners Limited (NOMAD) Neil Baldwin Stanford Capital Partners (Joint Broker) Patrick Claridge, Bob Pountney SI Capital (Joint Broker) Nick Emerson +44 (0) 203 36 8 3550 +44 (0) 20 3650 3650 +44 (0) 1483 413500 Notes to Editors About ImmuPharma PLC ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. For additional information about ImmuPharma please visit www.immupharma.co.uk . ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.